Human pluripotent stem cells such as embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs) provide unprecedented opportunities for cell therapies against intractable …

Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the
treatment of hematological malignancies. Although an important step forward for the field …

Polymorphisms in the human leukocyte antigen (HLA) class I genes can cause the rejection
of pluripotent stem cell (PSC)-derived products in allogeneic recipients. Disruption of the …

The prospect of transplanting cells and tissues without the risk of immune rejection or the
need for powerful immunosuppressive drugs is the 'holy grail'of transplantation medicine …

The molecular and physical information coded within the extracellular milieu is informing the
development of a new generation of biomaterials for tissue engineering. Several powerful …

Natural killer (NK) cells are attractive within adoptive transfer settings in cancer
immunotherapy due to their potential for allogeneic use; their alloreactivity is enhanced …

Background Human induced pluripotent stem cells (iPSCs) are expected to be useful for
regenerative medicine for many diseases. Many researchers have focused on and enabled …

The potential to generate virtually any differentiated cell type from embryonic stem cells
(ESCs) offers the possibility to establish new models of mammalian development and to …

The likelihood for immunological rejection of Human Leukocyte Antigens (HLA)-mismatched
induced pluripotent stem cells (iPSCs) limits their therapeutic potential. Here we show how a …

Mammalian development commences with the totipotent zygote which is capable of
developing into all the specialized cells that make up the adult animal. As development …